| Literature DB >> 33495757 |
Yun Shan Goh1,2, Jean-Marc Chavatte3, Alicia Lim Jieling3, Bernett Lee2, Pei Xiang Hor1,2, Siti Naqiah Amrun1,2, Cheryl Yi-Pin Lee1,2, Rhonda Sin-Ling Chee1,2, Bei Wang2, Chia Yin Lee2, Eve Zhi Xian Ngoh2, Cheng-I Wang2, Barnaby Edward Young3,4,5, Paul A Tambyah3,6, Shirin Kalimuddin7,8, Surinder Pada9, Seow-Yen Tan10, Louisa Jin Sun11, Mark I-Cheng Chen3,12, Yee-Sin Leo3,4,5,13, David C Lye3,4,5,13, Lisa F P Ng1,2,14,15,16,17, Raymond Tzer Pin Lin3,13, Laurent Renia1,2,17.
Abstract
Early detection of infection is crucial to limit the spread of coronavirus disease 2019 (COVID-19). Here we develop a flow cytometry-based assay to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein antibodies in individuals with COVID-19. The assay detects specific immunoglobulin M (IgM), IgA, and IgG in individuals with COVID-19 and also acquisition of all IgG subclasses, with IgG1 being the most dominant. The antibody response is significantly higher at a later stage of infection. Furthermore, asymptomatic individuals with COVID-19 also develop specific IgM, IgA, and IgG, with IgG1 being the most dominant subclass. Although the antibody levels are lower in asymptomatic infection, the assay is highly sensitive and detects 97% of asymptomatic infections. These findings demonstrate that the assay can be used for serological analysis of symptomatic and asymptomatic infections, which may otherwise remain undetected.Entities:
Keywords: COVID-19; IgG subclasses; S protein; SARS-CoV-2; antibodies; asymptomatic; serological; symptomatic
Mesh：
Substances：
Year: 2021 PMID： 33495757 PMCID： PMC7816583 DOI： 10.1016/j.xcrm.2021.100193
Source DB: PubMed Journal: Cell Rep Med ISSN： 2666-3791